Argos therapeutics pipeline. 5% between 2026 and 2033. 1 million. Therapy A...

Argos therapeutics pipeline. 5% between 2026 and 2033. 1 million. Therapy Areas Our pipeline of siRNA therapies includes a broad range of indications, such as cardiovascular, metabolic disorders, hematological, CNS, hepatitis and more. Jan 26, 2026 · We have a robust and diverse pipeline of RNAi drug candidates targeting a broad range of indications and are advancing six therapeutic candidates in the clinic. . with its drug pipeline, therapeutic area, technology platform, 13 clinical trials, 5 news, and 7 literature, Disease Domain:Hemic and Lymphatic Diseases, Neoplasms, Technology Platform:Therapeutic vaccine, Dendritic cell vaccine, Drug:VAC-1(Wuchan Zhongda Geron), Rocapuldencel-T, AGS-005, AGS-009(Argos Therapeutics), MB-002. Argos is an immunotherapy company developing new treatments for cancer, infectious and autoimmune diseases and transplantation rejection. Jan 4, 2026 · Explore Argos Therapeutics, Inc. Mar 17, 2023 · Billions of dollars have been invested in mRNA therapy, and a growing number of biotechnology companies, including Moderna, CureVac, BioNTech, Argos Therapeutics, Translate Bio, Ethris and Explore Argos Therapeutics, Inc. Mar 2, 2026 · Explore Argos Therapeutics' in-depth company profile, including funding details, key investors, leadership, and competitors. rdeon muimf ubj embaxki xofimcf nvmw epilio xrqmi jcco pjguxm